Cat. No.
MABL-1078
Application
block;, FC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
TH69
From
Recombinant Antibody
Specificity
This antibody binds the extracellular domain of human CD7. CD7 is expressed on the majority of immature and mature T-lymphocytes, and T cell leukemia. It is also found on natural killer cells, a small subpopulation of normal B cells and on malignant B cells. CD7 is useful in the identification of precursor T cells as well as an important marker for the identification of leukemic T cells.
Alternative Names
GP40; TP41; T-cell antigen CD7; T-cell leukemia antigen; T-cell surface antigen Leu-9; TH-69
UniProt
P09564
Immunogen
Application Notes
The therapeutic application of this antibody was explored to determine its potential use in the treatment of Human T-cell acute lymphocytic leukemia (ALL). When nude mice bearing approx. 2 g of tumor were treated with a single injection of CD7 antibody TH-69, 82.6% reached complete remission within 10 d whereas 13.0% showed partial remission. (PMID: 8904888). This antibody was also used in the development of a recombinant immunotoxin by linking the scFv version of this antibody to a truncated Pseudomonas exotoxin A fragment containing the catalytic domains II and III but lacking the receptor binding domain I. Approximately 20% of leukemic cells from a patient with CD7-positive acute T-cell leukemia kept in long-term primary culture for 30 cell generations were killed within 96 h after treatment with the toxin (PMID: 12019163). This antibody was also used in the generation of a fusion protein scFvCD7:sFasL, that is designed to have leukemia-restricted activity. wherein the scFv version of this antibody is genetically linked to soluble homotrimeric FasL. Treatment of T-cell acute lymphoblastic leukemia (T-ALL) cell lines and patient-derived T-ALL, peripheral T-cell lymphoma (PTCL), and CD7-positive acute myeloid leukemia (AML) cells with homotrimeric scFvCD7:sFasL revealed potent CD7-restricted induction of apoptosis that was augmented by conventional drugs, farnesyl transferase inhibitor L-744832, and the proteasome inhibitor bortezomib (PMID: 16332967).
Antibody First Published
Gramatzki et al. Monoclonal antibodies developed for diagnosis of T cell and very immature leukemias. Blut, 50 (1985), p. 216.
Note on publication
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
